Background and medico-political concerns In late 2025, claims from the U.S. administration regarding a potential link between prenatal acetaminophen (Tylenol) use and an increased risk of autism or ADHD in children sparked widespread public concern. These claims were based on an analysis of 46 prior studies suggesting that prolonged usage (over four weeks) might impact fetal neurodevelopment. This led to precautionary advisories from the U.S. Department of Health and Human Services (HHS) and the FDA.
New scientific evidence and expert reassurance However, by January 2026, public anxiety has subsided as major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM), reaffirmed the drug’s safety.
-
The Lancet Study: A large-scale analysis of 300,000 pregnancies recently published found no evidence that acetaminophen increases the risk of autism or ADHD.
-
Sibling-Comparison Method: A key strength of this new research is its use of sibling-comparison data to account for genetic and environmental factors—confounders that are central to the etiology of autism.
Current clinical guidance Obstetricians emphasize that leaving high fevers untreated poses a significantly greater risk to the fetus (such as neural tube defects or preterm birth) than taking the medication. Acetaminophen remains the primary and safest analgesic/antipyretic option for pregnant women, provided that:
-
It is taken at the lowest effective dose.
-
It is used for the shortest necessary duration.
-
Patients consult with their healthcare providers before use.
Source: https://edition.cnn.com/2026/01/16/health/tylenol-autism-new-research-review-wellness